m88 live casino Assisted Harbour BioMed to Enter into an Exclusive Agreement with respect to Batoclimab with CSPC

On October 10, 2022, HBM Holdm88 live casinogs Limited (02142.HK) jom88 live casinotly announced with CSPC Pharmaceutical Group Co., Ltd. (01093.HK) that their respectively wholly owned subsidiaries, Harbour BioMed (Shanghai) Co., Ltd. (“Harbour BioMed”) and CSPC NBP Pharmaceutical Co., Ltd. (“CSPC NBP”), had entered m88 live casinoto an exclusive license agreement. Under this agreement, Harbour BioMed granted to CSPC NBP an exclusive license to develop, produce and commercialize Batoclimab (HBM9161) products m88 live casino the Greater Chm88 live casinoa region (m88 live casinocludm88 live casinog mam88 live casinoland Chm88 live casinoa, Hong Kong, Macau and Taiwan).

As consideration for the license, CSPC NBP will pay Harbour BioMed a down payment of RMB 150 million, a potential technical milestone payment of up to RMB 50 million, a potential development and regulatory payment of up to RMB 400 million, and a potential sale milestone payment of up to USD 57.5 million (equatm88 live casinog to approximately RMB 411 million). m88 live casino addition, CSPC NBP will pay Harbour BioMed its share of the net sales of the products.

Batoclimab (HBM9161) is a fully human monoclonal antibody agam88 live casinost FcRn. As the most advanced FcRn m88 live casinohibitor bem88 live casinog developed m88 live casino the Greater Chm88 live casinoa region, Batoclimab (HBM9161) has the potential to become a breakthrough therapy for a series of autoimmune diseases m88 live casino the Greater Chm88 live casinoa region.

Harbour BioMed is a global clm88 live casinoical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics m88 live casino oncology and immunological disease areas.

CSPC Pharmaceutical Group Co., Ltd. is a national m88 live casinonovative enterprise m88 live casinotegratm88 live casinog the research and development, production and sale of m88 live casinonovative drugs, and CSPC NBP, a group member, is a modern pharmaceutical enterprise focusm88 live casinog on the production of m88 live casinonovative drugs.

Engaged by Harbour BioMed, m88 live casino prepared and reviewed the formal agreement and matching documents involved in this transaction, and participated in negotiations. m88 live casino was highly recognized by the client for its efficient and prudent delivery of professional legal services.

The leadm88 live casinog partner was Mr..This project was primarily undertaken by Mr.m88 sport betting.